Literature DB >> 14969782

Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses.

Mathias Zink1, Fritz A Henn, Johannes Thome.   

Abstract

Treatment-resistant schizophrenia often leads to combined application of antipsychotic drugs. We report first experience with the combination of olanzapine and amisulpride. Improvement of psychopathological state and side effects could be achieved, and drug doses were lower than under monotherapy. We thus conclude that this approach represents a useful therapeutic option.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14969782     DOI: 10.1016/j.eurpsy.2003.09.002

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  9 in total

1.  Augmentation of olanzapine in treatment-resistant schizophrenia.

Authors:  Mathias Zink
Journal:  J Psychiatry Neurosci       Date:  2005-11       Impact factor: 6.186

2.  A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design.

Authors:  Christian Schmidt-Kraepelin; Sandra Feyerabend; Christina Engelke; Mathias Riesbeck; Eva Meisenzahl-Lechner; Wolfgang Gaebel; Pablo-Emilio Verde; Henrike Kolbe; Christoph U Correll; Stefan Leucht; Stephan Heres; Michael Kluge; Christian Makiol; Andrea Neff; Christina Lange; Susanne Englisch; Mathias Zink; Berthold Langguth; Timm Poeppl; Dirk Reske; Euphrosyne Gouzoulis-Mayfrank; Gerhard Gründer; Alkomiet Hasan; Anke Brockhaus-Dumke; Markus Jäger; Jessica Baumgärtner; Thomas Wobrock; Joachim Cordes
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-09-05       Impact factor: 5.270

Review 3.  [Augmenting atypical antipsychotic medications with clozapin].

Authors:  M Zink; H Dressing
Journal:  Nervenarzt       Date:  2005-09       Impact factor: 1.214

4.  Remission of Psychosis in Treatment-resistant Schizophrenia Following a Seizure: A Case Report.

Authors:  Hena Jawaid; Sana Younus; Hanif Mesiya
Journal:  Innov Clin Neurosci       Date:  2016-06-01

5.  Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation.

Authors:  Marc Ziegenbein; Georg Wittmann; Stefan Kropp
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 6.  Practical issues with amisulpride in the management of patients with schizophrenia.

Authors:  Luca Pani; José M Villagrán; Vassilis P Kontaxakis; Köksal Alptekin
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

7.  Lorazepam-Resistant Catatonia in an Antipsychotic-Naïve 24-Year-Old with Psychotic Symptoms.

Authors:  Juan Pablo Lucchelli; Stamatia Kourakou; Laia Pérez de Lucia Bové; Daniel Diaz Rodriguez
Journal:  Case Rep Psychiatry       Date:  2020-04-03

8.  Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study.

Authors:  Young Sup Woo; Sung-Yong Park; Bo-Hyun Yoon; Won-Seok Choi; Sheng-Min Wang; Won-Myong Bahk
Journal:  Clin Psychopharmacol Neurosci       Date:  2022-08-31       Impact factor: 3.731

9.  Update on the management of symptoms in schizophrenia: focus on amisulpride.

Authors:  Ann M Mortimer
Journal:  Neuropsychiatr Dis Treat       Date:  2009-05-20       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.